Rejuvenation Technologies Inc.
mRNA therapeutics to extend healthspan entering clinical trials
Rejuvenation Technologies Inc. is active in the healthcare space based in San Francisco, CA, USA.
Profile
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
The company sits in the healthcare segment, where it competes on its core product or service.
San Francisco, CA, USA is where the company is located.
Its current recorded stage is Summer 2018.
The company reports a headcount in the 2 range.
Total disclosed funding stands at about $2.1M.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Summer 2018 |
| Total funding | $2,063,303 |
Website: www.rejuvenationtech.com
Browse related
Create a free account